Details of Disease

General Information of Disease (ID: DISBNYQL)

• Disease Name: Biliary tract cancer
• Synonyms: malignant tumour of biliary tract; malignant tumor of biliary tract; malignant neoplasm of biliary tree; malignant biliary tree neoplasm; cancer of biliary tree; biliary tree cancer
• Disease Class: 2C17: Biliary tract cancer
• Definition: A malignant neoplasm involving the biliary tree
• Disease Hierarchy:
  DISDE4BI: Liver cancer
  DISAT1Z9: Advanced cancer
  DISLWLHH: Biliary tract neoplasm
  DISBNYQL: Biliary tract cancer
• ICD Code:
  ICD-11: ICD-11: 2C17
  ICD-10: ICD-10: C24.9
  Expand ICD-11: '2C17
  Expand ICD-10: 'C24.9
• Disease Identifiers:
  MONDO ID: MONDO_0003060
  MESH ID: D001661
  UMLS CUI: C0750952
  MedGen ID: 155474
  SNOMED CT ID: 363415003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bevacizumab	DMSD1UN	Approved	Monoclonal antibody	[1]
Durvalumab	DM4PVDY	Approved	Monoclonal antibody	[2]
Fluorouracil	DMUM7HZ	Approved	Small molecular drug	[3]
Gemcitabine	DMSE3I7	Approved	Small molecular drug	[4]

This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
acelarin	DMY96O3	Phase 3	Small molecular drug	[5]
BNT141	DM9XRBT	Phase 2	Antibody	[6]
DKN-01	DMOHT5V	Phase 2	Antibody	[7]
LY2801653	DM0KJDY	Phase 2	Small molecular drug	[2]
ZW25	DMRLZA1	Phase 2	Antibody	[8]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 12 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
DCK	TTJOCE4	Limited	Altered Expression	[9]
IDH1	TTV2A1R	Limited	Genetic Variation	[10]
CCKAR	TTCG0AL	Strong	Genetic Variation	[11]
CDA	TTQ12RK	Strong	Genetic Variation	[12]
CDH6	TT9QHUK	Strong	Altered Expression	[13]
CRTC1	TT4GO0F	Strong	Biomarker	[14]
CRTC2	TTFWETR	Strong	Biomarker	[14]
FABP5	TTNT2S6	Strong	Biomarker	[15]
IKZF3	TTCZVFZ	Strong	Biomarker	[16]
PLOD2	TT8MEUD	Strong	Altered Expression	[17]
RRM1	TTWP0NS	Strong	Biomarker	[18]
SEPTIN6	TTAGE7U	Strong	Altered Expression	[19]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC28A3	DT4YL5R	Strong	Genetic Variation	[12]

This Disease Is Related to 15 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ELF3	OTUTLEQO	Limited	Biomarker	[20]
PPFIBP2	OTXQO55Y	Limited	Genetic Variation	[21]
PRKACB	OT6RMDCE	Limited	Biomarker	[20]
ABCG8	OTIJ76XW	Strong	Genetic Variation	[22]
BTC	OTW4B2O0	Strong	Biomarker	[23]
CDK10	OTKP7TTR	Strong	Biomarker	[24]
CDO1	OTLG1P77	Strong	Posttranslational Modification	[25]
EIF6	OTEXMUED	Strong	Altered Expression	[26]
GFM1	OTUN4V3N	Strong	Genetic Variation	[27]
IHH	OT1DWGXC	Strong	Biomarker	[28]
LRPAP1	OT6DVD2Q	Strong	Biomarker	[22]
MPC1	OT6DYFUO	Strong	Altered Expression	[29]
OXA1L	OTS0BFRD	Strong	Biomarker	[30]
PRC1	OTHD0XS0	Strong	Altered Expression	[31]
SEPTIN2	OT3G33TM	Strong	Altered Expression	[19]

References

• [1] Angiogenesis in biliary tract cancer: targeting and therapeutic potential. Expert Opin Investig Drugs. 2021 Apr;30(4):411-418.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Fluorouracil FDA Label
• [4] Gemcitabine FDA Label
• [5] ClinicalTrials.gov (NCT04163900) Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT04683939) Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors. U.S.National Institutes of Health.
• [7] ClinicalTrials.gov (NCT03818997) Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer (DYNAMIC). U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT04466891) A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers. U.S. National Institutes of Health.
• [9] DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study.Oncotarget. 2017 Jul 6;8(46):81394-81404. doi: 10.18632/oncotarget.19037. eCollection 2017 Oct 6.
• [10] Exome sequencing of 22 genes using tissue from patients with biliary tract cancer.APMIS. 2020 Jan;128(1):3-9. doi: 10.1111/apm.13003.
• [11] Variants in CCK and CCKAR genes to susceptibility to biliary tract cancers and stones: a population-based study in Shanghai, China.J Gastroenterol Hepatol. 2013 Sep;28(9):1476-81. doi: 10.1111/jgh.12278.
• [12] Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.Oncology. 2015;89(6):345-50. doi: 10.1159/000439222. Epub 2015 Sep 30.
• [13] Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma.Epigenetics. 2016 Nov;11(11):780-790. doi: 10.1080/15592294.2016.1227899. Epub 2016 Sep 3.
• [14] mTOR Inhibitors in Advanced Biliary Tract Cancers.Int J Mol Sci. 2019 Jan 24;20(3):500. doi: 10.3390/ijms20030500.
• [15] Expression of fatty-acid-binding protein 5 in intrahepatic and extrahepatic cholangiocarcinoma: the possibility of different energy metabolisms in anatomical location.Med Mol Morphol. 2020 Mar;53(1):42-49. doi: 10.1007/s00795-019-00230-9. Epub 2019 Aug 20.
• [16] PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.Eur J Cancer. 2018 Mar;92:11-19. doi: 10.1016/j.ejca.2017.12.028. Epub 2018 Feb 3.
• [17] Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.Ann Surg Oncol. 2018 Nov;25(12):3728-3737. doi: 10.1245/s10434-018-6670-8. Epub 2018 Aug 13.
• [18] Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis.Crit Rev Oncol Hematol. 2019 Sep;141:82-94. doi: 10.1016/j.critrevonc.2019.06.001. Epub 2019 Jun 8.
• [19] Expression of septin 2 and association with clinicopathological parameters in colorectal cancer.Oncol Lett. 2019 Sep;18(3):2376-2383. doi: 10.3892/ol.2019.10528. Epub 2019 Jun 26.
• [20] Genomic spectra of biliary tract cancer.Nat Genet. 2015 Sep;47(9):1003-10. doi: 10.1038/ng.3375. Epub 2015 Aug 10.
• [21] Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer.Eur J Cancer. 2013 May;49(7):1725-40. doi: 10.1016/j.ejca.2012.12.002. Epub 2013 Jan 5.
• [22] Cholesterol metabolism gene polymorphisms and the risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China.Carcinogenesis. 2011 Jan;32(1):58-62. doi: 10.1093/carcin/bgq194. Epub 2010 Nov 9.
• [23] Identification of potential biomarkers for diagnosis of pancreatic and biliary tract cancers by sequencing of serum microRNAs.BMC Med Genomics. 2019 May 16;12(1):62. doi: 10.1186/s12920-019-0521-8.
• [24] CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells.Oncol Rep. 2012 Apr;27(4):1266-76. doi: 10.3892/or.2011.1617. Epub 2011 Dec 30.
• [25] Methylated promoter DNA of CDO1 gene and preoperative serum CA19-9 are prognostic biomarkers in primary extrahepatic cholangiocarcinoma.PLoS One. 2018 Oct 16;13(10):e0205864. doi: 10.1371/journal.pone.0205864. eCollection 2018.
• [26] Eukaryotic translation initiation factor 6 overexpression plays a major role in the translational control of gallbladder cancer.J Cancer Res Clin Oncol. 2019 Nov;145(11):2699-2711. doi: 10.1007/s00432-019-03030-x. Epub 2019 Oct 4.
• [27] Essential role of polymorphism of Gab1, EGFR, and EGF for the susceptibility of biliary tract cancer.Tumour Biol. 2014 Dec;35(12):12497-508. doi: 10.1007/s13277-014-2568-7. Epub 2014 Sep 14.
• [28] Identification of the transforming activity of Indian hedgehog by retroviral expression screening.Cancer Sci. 2010 Jan;101(1):60-4. doi: 10.1111/j.1349-7006.2009.01355.x. Epub 2009 Sep 9.
• [29] Mitochondrial pyruvate carrier modulates the epithelial-mesenchymal transition in cholangiocarcinoma.Oncol Rep. 2018 Mar;39(3):1276-1282. doi: 10.3892/or.2017.6172. Epub 2017 Dec 20.
• [30] Claudin-4 differentiates biliary tract cancers from hepatocellular carcinomas.Mod Pathol. 2006 Mar;19(3):460-9. doi: 10.1038/modpathol.3800549.
• [31] The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells.Oncotarget. 2016 Jan 5;7(1):745-58. doi: 10.18632/oncotarget.6378.